课题基金 / 基金详情

项目摘要

项目成果

THOMAS D. SCHMITTGEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT: PILOT PROJECT Pancreatic ductal adenocarcinoma (PDAC) is the fourth most lethal cancer in the USA and is predicted to become the second most deadly cancer in the country by 2030. Blacks display an overall significantly greater age adjusted incidence and mortality rate from PDAC compared to Whites. Recognized risk factors for PDAC while at a higher prevalence in Blacks than Whites, does not account for the increased incidence and mortality from PDAC in Blacks, suggesting a biological explanation for the observed differences. The process of acinar ductal metaplasia (ADM) precedes PDAC precursor lesion formation. Since ADM is the earliest known precursor lesion for PDAC, acinar to ductal transdifferentiation is a key phase in the initiation of pancreatic cancer. We hypothesize that Blacks undergo ADM to a greater degree than Whites and that genetic as well as epigenetic factors account for this disparity. Specific Aim 1 will investigate the degree of in vitro ADM quantitatively using tissue samples from human pancreata of heathy donors obtained from pancreatic islet procurement centers. Non-islet fractions containing the primary, human pancreatic acini will be cultured and functionality will be demonstrated by inducing ADM in vitro. The duct formation doubling time and fold change in expression of acinar and ductal genes between Black and White donors will determine if ADM is enhanced in Blacks. Expression arrays will be used to identify the top genetic drivers of ADM in Blacks and Whites. Promoter DNA methylation will determine if epigenetic changes are responsible for the change in gene expression between Blacks and Whites. Specific Aim 2 will perform a genetic association study to identify SNPs in the genetic drivers of ADM using nested, case-control cohorts of PDAC data. Successful completion of this project will establish that racial disparities exist for the ability of pancreatic acini to undergo ADM. We will have also identified a gene expression signature that will characterize the ADM process by race as well as genetic and epigenetic factors that drive ADM in Blacks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
R21 MPI microRNA directed therapy for treating early stage pancreatic cancer
  • 批准号:
    10577609
  • 项目类别:
  • 资助金额:
    $17.82万
  • 财政年份:
    2023
  • 负责人:
    THOMAS D. SCHMITTGEN
  • 依托单位:
Pilot Project 3: Contribution of Racial Disparity towards the Early Development of Pancreatic Cancer
  • 批准号:
    10006214
  • 项目类别:
  • 资助金额:
    $11.3万
  • 财政年份:
    2018
  • 负责人:
    THOMAS D. SCHMITTGEN
  • 依托单位:
Project 3 ADM
  • 批准号:
    10762126
  • 项目类别:
  • 资助金额:
    $11.6万
  • 财政年份:
    2018
  • 负责人:
    THOMAS D. SCHMITTGEN
  • 依托单位:
miRNA Biomarkers for Hepatocellular Carcinoma Associated with Viral Hepatitis
  • 批准号:
    8520269
  • 项目类别:
  • 资助金额:
    $16.77万
  • 财政年份:
    2012
  • 负责人:
    THOMAS D. SCHMITTGEN
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: